Become A Featured Company

Levitee Labs Announces Closing of Oversubscribed Private Placement

Ryan Allway

February 17th, 2021

Psychedelics

Levitee Labs Inc. (“Levitee“), a private British Columbia company in the alternative medicine and integrative wellness space, announced today that it has closed (the “Closing“) a heavily oversubscribed non-brokered private placement (the “Private Placement“) through the issuance of a total of 21,140,000 subscription receipts (each, a “Subscription Receipt“) of the Company at a price of $0.50 per Subscription Receipt, for aggregate gross proceeds of $10,570,000.

Each Subscription Receipt will be convertible, without additional payment, into one unit of the Company (a “Unit“) following the satisfaction of the following conditions (the “Escrow Release Conditions“): (i) Levitee obtaining a final receipt on behalf of each of the securities regulatory authorities in the Provinces of Canada in which Subscription Receipts have been sold for a final prospectus qualifying the issuance of the Shares (defined herein) and the Warrants (defined herein); and (ii) Levitee receiving conditional approval for the listing of the Shares on the Canadian Securities Exchange (the “Exchange“).

Each Unit will consist of one common share (a “Share“) of the Company and one-half of one common share purchase warrant (each whole warrant, a “Warrant“). Each Warrant will be exercisable into one Share at a price of $0.75 per Share for a period of three (3) years following the issuance date. Cash finder’s fees and finder’s warrants (each, a “Finder’s Warrant“) will be issued on release of the funds from the Private Placement to the Company on satisfaction of the Escrow Release Conditions. Each Finder’s Warrant will be exercisable for two (2) years into one Share at a price of $0.75 per Share.

The gross proceeds raised in connection with the Private Placement will be held in escrow pending satisfaction of the Escrow Release Conditions. Levitee intends to use the proceeds from the Private Placement to fund acquisitions, working capital purposes and for fees associated with listing the Shares on the Exchange (the “Listing“).

With the Private Placement closed, the Company now intends to pursue the Listing as expediently as possible.

“We are pleased to have completed our oversubscribed go-public financing. This serves as a cornerstone to achieving our mission of transforming the integrative wellness industry through the inclusion of psychedelic medicine. We aim to be the first publicly listed company within the psychedelic space to achieve significant revenue and cashflow. We would like to thank our shareholders, advisors, and agents for their support” stated Pouya Farmand, Chief Executive Officer of the Company.

This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to the account or benefit of a U.S. person absent an exemption from the registration requirements of such Act.

About Levitee Labs

Levitee Labs is establishing itself as a leader in the integrative wellness space. Through leveraging an M&A regimen that focuses on the centralization of complementary integrative wellness assets, Levitee Labs aims to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies.

The company’s current portfolio of assets includes Sporeo and MONKE Nutraceuticals. Sporeo manufacturers the first commercial grade offering of spawn and substrate and has mass distribution agreements in place with leading global distributors. Sporeo is currently developing an ecommerce platform that will be a centralized portal for all mushroom cultivation needs. MONKE specializes in the development and distribution of premium functional mushroom supplements. This adaptogenic product line was formulated to enhance consumers’ wellbeing. Levitee Labs aims to catalyze access to compounds and alternative medicines that enhances the wellbeing of society.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading